Program
varegacestat
Also written as “AL102” and “BMS-986115”.
Its studies are mostly in Desmoid Tumors, led by 2 companies.
Drug pageBMS-986115: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Immunomeits history only | 51 open or running | phase 3since Apr 23, 2021 | Apr 23, 2021 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 1since Nov 11, 2013 | Nov 11, 2013 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 11, 2013First study: phase 1 study in Various Advanced CancerFirst studyNCT01986218 · 36 enrolled · United States, Australia, Canada
- Feb 29, 2024Named varegacestatINNProposed as its International Nonproprietary Name in WHO's List 130 · before, AL102, BMS-986115
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Bristol-Myers Squibb leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01986218Various Advanced Cancer · United States, Australia, Canada | 1 | Terminated | Mar 2016 | 36 |
How it is read
Names in the registry
- “varegacestat”, 4 entries
- “AL102”, 1 entry
- “BMS-986115”, 1 entry
Conditions, from the studies’ own filings
- Desmoid Tumors, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.